retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

Similarly, the REWIND trial showed a stronger impact of dulaglutide on nonfatal stroke (HR 0.76

Morgan GLP-1 supply is expected to increase across the globe GLP-1 penetration remains low globally, with roughly 7% of diabetes patients and 2% of the obese population currently using these medications

The clinical guidelines and recommendations from esteemed health organizations such as the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consistently endorse the use of GLP-1 analogues for specific patient associates

Importantly, most subjects with exenatide-induced volume contraction were receiving drugs that inhibit the renin-angiotensin system and aldosterone formation

The National Institute of Drug Abuse (NIDA) announced they are sponsoring a clinical trial testing whether Tirzepatide could effectively treat cannabis use disorder

Nauck MA, Quast DR, Wefers J, et al